EcoDrugPlus

Cytochrome P450 3a56-Like

Ensembl ID : ENSPREG00000000045
Gene Symbol: LOC103462633
2 Cross references
535 Possible Orthologues:

Cytochrome P450 3a56-Like

Ensembl ID : ENSPREG00000002452
Gene Symbol: LOC103476433
2 Cross references
529 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSPREG00000014438
Gene Symbol: CYP19A1
3 Cross references
244 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSPREG00000004786
Gene Symbol: LOC103460628
3 Cross references
188 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPREG00000014654
Gene Symbol: LOC103471988
3 Cross references
191 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPREG00000016164
Gene Symbol: LOC103479830
3 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPREG00000009202
Gene Symbol: LOC103476699
3 Cross references
214 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSPREG00000012064
Gene Symbol: DGAT1
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSPREG00000019007
Gene Symbol: LOC103478641
3 Cross references
190 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSPREG00000022646
Gene Symbol: DHODH
3 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSPREG00000014688
Gene Symbol: DPYD
3 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSPREG00000005719
Gene Symbol: DDR2
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).